## **Supplemental Material**

# Fluconazole increases osmotic water transport in renal collecting duct through effects on aquaporin 2 trafficking

Tanja Vukićević<sup>1</sup>¶, Christian Hinze<sup>1,2,3</sup>¶, Sandrine Baltzer<sup>1</sup>, Nina Himmerkus<sup>4</sup>, Catarina Quintanova<sup>4</sup>, Kerstin Zühlke<sup>1</sup>, Friederike Compton<sup>2,3</sup>, Robert Ahlborn<sup>5</sup>, Alessandro Dema<sup>1</sup>, Jenny Eichhorst<sup>6</sup>, Burkhard Wiesner<sup>6</sup>, Markus Bleich<sup>4</sup>, Kai M. Schmidt-Ott<sup>1,2,3\*</sup> & Enno Klussmann<sup>1,7\*</sup>

<sup>¶</sup>These authors contributed equally to this work.

# Affiliations

<sup>1</sup>Max Delbrück Center for Molecular Medicine Berlin (MDC), Germany

<sup>2</sup>Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin

Berlin, Germany.

<sup>3</sup>Berlin Institute of Health, Berlin, Germany.

<sup>4</sup>Department of Physiology, Christian Albrechts University Kiel, Germany

<sup>5</sup>Information Technology Department, Charité - Universitätsmedizin Berlin, Germany

<sup>6</sup>Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany

<sup>7</sup>DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany

Running Title: Fluconazole causes antidiuresis

#### \*Corresponding authors

Enno Klussmann Anchored Signaling Max Delbrück Center for Molecular Medicine (MDC) In the Helmholtz Association Robert-Rössle-Strasse 10 13125 Berlin Germany Tel. +49 (0)30 9406 2596 FAX. +49 (0)30 9406 2593 enno.klussmann@mdc-berlin.de Kai M. Schmidt-Ott Molecular and Translational Kidney Research Max Delbrück Center for Molecular Medicine (MDC) In the Helmholtz Association Robert-Rössle-Strasse 10 13092 Berlin Germany Tel. +49 (0)30 9406 2512 Kai.schmidt-ott@mdc-berlin.de

# Content

Supplemental Figure 1: Scheme showing animal treatment

Supplemental Figure 2 Supplemental Figure 2: Fluconazole does not affect (A) creatinine clearance, (B) water or (C) food intake of mice.

Supplemental Figure 3: (A) Without trans-epithelial osmotic gradient the application of 50  $\mu$ M fluconazole does not induce trans-epithelial water flow across epithelia of isolated CCDs. (B) Diameter of mouse CCDs during water flux measurements at a given osmotic gradient (300/150 mosm/kg) does not change in response to DMSO, fluconazole (50  $\mu$ M) or forskolin (30  $\mu$ M).

Supplemental Figure 4. Fluconazole does not alter AQP2 mRNA abundance in primary IMCD cells and mice

# **Supplemental Figure 1**



Supplemental Figure 1: Scheme depicting regimes of mouse treatments.

Supplemental Figure 2



Supplemental Figure 2: Fluconazole does not affect (A) creatinine clearance, (B) water or (C) food intake of mice. The creatinine clearance in baseline male mice was calculated as a measure for the glomerular filtration rate (GFR) according to Dunn et al., 2004.<sup>17</sup>

#### **Supplemental Figure 3**



В

constant pressure 300 mosm/kg basolateral 0.20-0.16 fluorescence increment [rel. intensity/min] 0.12 Relative Intensity 1.3-0.08 1.2 1.1 0.04 TTTTTTTTT 0.00 Fluconazole 0.9 -0.04 -80 -40 40 80 120 160 200 -0.08ò time (s) 20 DMSO diameter [µm] FSK Fluconazole symetric 16 Fluconazole, symmetric 300 mosm/kg 0 80 ŝ 6 time [s]

Fluconazole 300 mosm/kg luminal

Supplemental Figure 3. (A) Without trans-epithelial osmotic gradient the application of 50 µM fluconazole does not induce trans-epithelial water flow across epithelia of isolated CCDs. The scheme depicts the experimental setting; control solution with 300 mosm/kg (145 mM NaCl, 0.4 mM KH<sub>2</sub>PO4, 1.6 mM K<sub>2</sub>HPO4, 1 mM MgCl<sub>2</sub>, 1.3 mM Cagluconate, 5 mM Glucose, pH 7.4) on both sides, luminally supplemented with 50 µM 150 kDa FITC dextran. Change of relative fluorescence intensity over time, application of basolateral 50 µM fluconazole at time point 0s. Fluorescence increment values for n = 3 CCD of 3 C57Bl6J mice (8 weeks). (B) Diameter of mouse CCDs during water flux measurements at a given osmotic gradient (300/150 mosm/kg) does not change in response to DMSO, fluconazole (50 µM) or forskolin (30 µM). Luminal diameters were taken at time point -80s, 0 s, 80s and 160s. There was no systematic change in the diameter over time or after applications of the agents.

## **Supplemental Figure 4**



Supplemental Figure 4. Fluconazole does not alter AQP2 mRNA abundance in primary IMCD cells and mouse kidney. Semiquantitative analysis of the effects of forskolin and fluconazole on AQP2 mRNA levels. (A) IMCD cells were left untreated or stimulated with forskolin (FSK,  $30 \mu$ M) or fluconazole (Flu,  $50 \mu$ M) for 4 h or every 24 h over a period of 96 h. Relative levels of AQP2 mRNA were determined by real-time PCR. Shown are means ± SEM of three independent experiments with duplicates each, \*p=0.0169, \*\*\*p<0.0001. (B) Non water-deprived mice were treated every 24 h over a period of 96 h with fluconazole (i.p. injections; 80 mg/kg) or with 0.9% NaCl. Whole kidney lysates were prepared and relative levels of AQP2 mRNA were determined by real-time PCR. n = 5 animals per NaCl group and n = 4 animals per fluconazole group (mean ± SEM).